Dutasteride prevents the growth response to testosterone in benign and androgen-sensitive malignant prostate cells

International Journal of Clinical and Experimental Medicine

Volumn 3, Issue 3, 2010, Pages 245-247

  Alisky, Joseph M ^a   Tang, Yaqiong ^b   Habermehl, Gabriel K ^b   Iczkowski, Kenneth A ^b  

^a TOTAL   (France)

^b UNIVERSITY OF COLORADO   (United States)

Author keywords

Bph; Dutasteride; Prostate cancer; Testosterone

Indexed keywords

ANDROGEN; DUTASTERIDE; TESTOSTERONE;

ALOPECIA; ANIMAL CELL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CELL STRAIN LNCAP; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; GROWTH INHIBITION; HORMONE RESPONSE; HORMONE SENSITIVITY; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PROSTATE CANCER; PROSTATE HYPERTROPHY; RAT;

RATTUS;

EID: 77956643502     PISSN: None     EISSN: 19405901     Source Type: Journal    
DOI: None     Document Type: Article

References (10)

1. Bassil N, Alkaade S, Morley JE. The benefits and risks of testosterone replacement therapy: a review. Ther Clin Risk Manag 2009; 5: 427-48.
2. Morgentaler A. Rapidly shifting concepts regarding androgens and prostate cancer. Scientific World J 2009; 9: 685-90.
3. Delongchamps NB, de la Roza G, Chandan V, Jones R, Sunheimer R, Threatte G, Jumbelic M, Haas GP. Evaluation of prostatitis in autopsied prostates--is chronic inflammation more associated with benign prostatic hyperplasia or cancer? J Urol 2008; 179: 1736-40.
4. Soos G, Tsakiris I, Szanto J, Turzo C, Haas PG, Dezso B. The prevalence of prostate carcinoma and its precursor in Hungary: an autopsy study. Eur Urol 2005; 48: 739-44.
5. Stamatiou K, Alevizos A, Agapitos E, Sofras F. Incidence of impalpable carcinoma of the prostate and of non-malignant and precarcinomatous lesions in Greek male population: an autopsy study. Prostate 2006; 66: 1319-28.
6. Wu HC, Hsieh JT, Gleave ME, Brown NM, Pathak S, Chung LW. Derivation of androgenindependent human LNCaP prostatic cancer cell sublines: role of bone stromal cells. Int J Cancer 1994; 57: 406-12.
7. Gao AC, Lou W, Ichikawa T, Denmeade SR, Barrett JC, Isaacs JT. Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1-13.2. Prostate 1999; 38: 46-54.
8. Iczkowski KA, Omara-Opyene AL, Kulkarni TR, Pansara M, Shah GV. Paracrine calcitonin in prostate cancer is linked to CD44 variant expression and invasion. Anticancer Res 2005; 25: 2075-83.
9. Wang C, Swerdloff R, Kipnes M, Matsumoto AM, Dobs AS, Cunningham G, Katznelson L Weber TJ, Friedman TC, Snyder P, Levine HL. New testosterone buccal system (Striant) delivers physiological testosterone levels: pharmacokinetics study in hypogonadal men. J Clin Endocrinol Metab 2004; 89: 3821-9.
10. Li J, Kim J. Molecular profiles of finasteride effects on prostate carcinogenesis. Cancer Prev Res (Phila Pa) 2009; 2: 518-24.